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Introduction: aHUS is a rare, genetic, life-threatening disease of uncontrolled, chronic 
complement activation leading to TMA and severe end-organ damage. During the first 
clinical manifestation, end-stage renal disease (ESRD) or death occurs in approximately 
33 to 40% of patients, and within one year of diagnosis, up to 65% have permanent 
renal damage, ESRD, or die despite receiving plasma exchanges/plasma infusions 
(PE/PI). Many aHUS pts are also misdiagnosed as TTP, which also results in poor 
outcomes with PE/PI. Hence, early diagnosis and effective treatment are critical to halt 
and/or prevent systemic complement-mediated damage. Ecu, a terminal complement 
inhibitor, is approved for the treatment of aHUS. Herein, we report safety and efficacy 
results of Ecu from the largest prospective study in aHUS to date.  
Methods: This was an open-label, single-arm, Phase 2 trial of Ecu in adult aHUS pts. 
Inclusion criteria included platelet count <150 x109/L and LDH ≥1.5 ULN. Pts with STEC-
HUS (shiga toxin + E. coli) and severe ADAMTS13 deficiency (<5%) were excluded. An 
identified complement gene mutation was not required for admission. The primary 
endpoint was complete TMA response at 26 wks (normalization of platelets and LDH, and 
≥25% improvement in serum creatinine from baseline (BL) on 2 consecutive 
measurements ≥4 wks apart).  
Results: 41 pts enrolled and 38 (93%) received 26 wks of treatment (Table). 30 pts 
(73%) were newly diagnosed, with a median of 2 wks to the first dose of Ecu. 6 pts 
(15%) had no PE/PI during the current clinical manifestation. At wk 26, 30 pts (73%) 
achieved complete TMA response, 36 (88%) achieved hematologic normalization, and 40 
(98%) achieved platelet count normalization. Mean increase in platelet count from BL 
was 119x109/L (P<0.0001). Mean eGFR increase from BL was 26.1 mL/min/1.73 m2 
(P<0.0001). Platelet count (Fig 1) and eGFR (Fig 2) increased significantly from BL 
through wk 26. Of 24 pts on dialysis at BL, 20 (83%) discontinued dialysis by wk 26. Two 
pts not on dialysis at BL initiated and remained on dialysis through 26 wks. QoL 
significantly improved. Ecu was generally safe and well tolerated. Two pts had 
meningococcal infections, one of whom continued Ecu. No pts died.  
Conclusions: Ecu normalized hematologic parameters and significantly improved renal 
function and QoL. The results of this prospective study confirm that Ecu inhibits 
complement-mediated TMA in adult aHUS pts, and point to the importance of early and 
accurate diagnosis, including ADAMTS13 testing. Due to high morbidity and mortality in 
aHUS despite PE/PI, recent guidelines recommend Ecu as first-line treatment in adults 
once an unequivocal diagnosis is made. The current data validate this treatment 
approach. This study is ongoing. 
 
 
 Table: Baseline characteristics  
Baseline Demographics and Disease Characteristics (N=41)  
Age, mean (SD), y  40.3 (15.3)  
Female sex, n (%)  28 (68)  
Identified complement regulatory protein mutation or auto-antibody, n (%)  20 (49)  
Time from aHUS diagnosis until screening (mo), median (range)  0.8 (0–311)  
Newly diagnosed pts, n (%)  30 (73)  
Duration of current clinical manifestation of aHUS (mo), median (range)  0.5 (0.0–19.1)  
PE/PI during current clinical manifestation of aHUS, n (%)  35 (85)  
Dialysis at BL, n (%)  24 (59)  
Prior renal transplant, n (%)  9 (22)  
Plt count <150x109/L, n (%)  27 (66)  
LDH >ULN, n (%)   32 (78)  
eGFR ≤60 mL/min/1.73 m2, n (%)  41 (100)  
Efficacy Outcomes  
Complete TMA response*, n (%)  30 (73)  
Hematologic normalization†, n (%)  36 (88)  
Plt count normalization‡, n (%)  40 (98)  
Plt count increase (x109/L), mean (95% CI)  
119 (94; 145)  
P<0.0001  
eGFR increase from BL ≥15 mL/min/1.73 m2,n (%)  22 (54)  
eGFR increase from BL (mL/min/1.73 m2), mean (95% CI)  
26.1 (19.8; 32.4)  
P<0.0001  
CKD improvement ≥1 stage from BL, n (%)  26 (63)  
*Complete TMA response: normalization of plts and LDH, and ≥25% improvement in 
serum creatinine from BL on 2 consecutive measurements ≥4 wk apart.  
†Complete hematologic response: plt and LDH normalization at ≥2 consecutive 
measurements ≥4 wk apart.  
‡Plt count normalization: plt count ≥150x109/L ≥2 consecutive measurements ≥4 wk 
apart.  
   
 
 
 
 
 
 
 
 
 Figure 1: Platelet count improvement through 26 weeks.  
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Figure 2: eGFR improvement through 26 weeks.
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